// App-Quantinova.ai

267 : Preclinical investigation of the HSP90 inhibitor, ganetespib, in combination with FDA-approved cytotoxic agents for their potential anti-tumor effects on human neuroendocrine tumors

Researchers

Presenter

  • Chung Wong

Principal Investigators

  • Evan Vosburgh

  • Arnold Levine

  • David Proia

  • Eugenia Xu

Medical Centers

  • Raymond and Beverly Sackler Foundation, New Brunswick, NJ

  • Institute for Advanced Study, Princeton, NJ.

  • Synta Pharmaceuticals Corporation, Lexington, MA.

Locations

  • United States

Companies

  • Synta Pharmaceutical

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreatic Neuroendocrine Tumors

  • Acute myelocytic leukemia

  • Neuroendocrine tumors

  • Gynaecological cancer

  • Breast cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • ganetespib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved